These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29507061)

  • 21. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.
    Castellino S; Moss L; Wagner D; Borland J; Song I; Chen S; Lou Y; Min SS; Goljer I; Culp A; Piscitelli SC; Savina PM
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3536-46. PubMed ID: 23669385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.
    Chen N; Wen L; Lau H; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):789-97. PubMed ID: 22037879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea.
    Mancuso AM; Gandhi MA; Slish J
    J Pharm Pract; 2018 Apr; 31(2):195-201. PubMed ID: 28490220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia.
    Lang JE; Hornik CP; Elliott C; Silverstein A; Hornik C; Al-Uzri A; Bosheva M; Bradley JS; Borja-Tabora CFC; Di John D; Mendez Echevarria A; Ericson JE; Friedel D; Gonczi F; Isidro MGD; James LP; Kalocsai K; Koutroulis I; Laki I; Ong-Lim ALT; Nad M; Simon G; Syed S; Szabo E; Benjamin DK; Cohen-Wolkowiez M;
    Pediatr Infect Dis J; 2022 Jul; 41(7):556-562. PubMed ID: 35675525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
    Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents.
    Gonzalez D; James LP; Al-Uzri A; Bosheva M; Adler-Shohet FC; Mendley SR; Bradley JS; Espinosa C; Tsonkova E; Moffett K; Marquez L; Simonsen KA; Stoilov S; Boakye-Agyeman F; Jasion T; Hornik CP; Hernandez R; Benjamin DK; Cohen-Wolkowiez M
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the N-acetylation polymorphism in solithromycin metabolism.
    Hein DW; Doll MA
    Pharmacogenomics; 2017 Jun; 18(8):765-772. PubMed ID: 28625123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solithromycin monotherapy for treatment of community-acquired bacterial pneumonia: A meta-analysis of randomised controlled trials.
    Wen J; Chen F; Zhao M; Wang X
    Int J Clin Pract; 2019 May; 73(5):e13333. PubMed ID: 30810253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial activity of solithromycin and levofloxacin against a murine pneumonia mixed-infection model caused by Streptococcus pneumoniae and anaerobic bacteria.
    Kato H; Yamagishi Y; Hagihara M; Yokoyama Y; Suematsu H; Asai N; Koizumi Y; Mikamo H
    J Infect Chemother; 2019 Apr; 25(4):311-313. PubMed ID: 30287186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
    Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
    Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009).
    Farrell DJ; Castanheira M; Sader HS; Jones RN
    J Infect; 2010 Dec; 61(6):476-83. PubMed ID: 20831882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.
    Putnam SD; Sader HS; Farrell DJ; Biedenbach DJ; Castanheira M
    Int J Antimicrob Agents; 2011 Jan; 37(1):39-45. PubMed ID: 21075602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents.
    Gonzalez D; Palazzi DL; Bhattacharya-Mithal L; Al-Uzri A; James LP; Bradley J; Neu N; Jasion T; Hornik CP; Smith PB; Benjamin DK; Keedy K; Fernandes P; Cohen-Wolkowiez M
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2572-6. PubMed ID: 26883693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniae.
    Figueira M; Fernandes P; Pelton SI
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5533-8. PubMed ID: 27401563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012.
    Farrell DJ; Mendes RE; Jones RN
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2432-4. PubMed ID: 25605359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The solithromycin journey-It is all in the chemistry.
    Fernandes P; Martens E; Bertrand D; Pereira D
    Bioorg Med Chem; 2016 Dec; 24(24):6420-6428. PubMed ID: 27595539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
    Kumar S; Tan EY; Hartmann G; Biddle Z; Bergman AJ; Dru J; Ho JZ; Jones AN; Staskiewicz SJ; Braun MP; Karanam B; Dean DC; Gendrano IN; Graves MW; Wagner JA; Krishna R
    Drug Metab Dispos; 2010 Mar; 38(3):474-83. PubMed ID: 20016053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.
    Slatter JG; Stalker DJ; Feenstra KL; Welshman IR; Bruss JB; Sams JP; Johnson MG; Sanders PE; Hauer MJ; Fagerness PE; Stryd RP; Peng GW; Shobe EM
    Drug Metab Dispos; 2001 Aug; 29(8):1136-45. PubMed ID: 11454733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.